Overexpression of cytochrome P450 1A1 and its novel spliced variant in ovarian cancer cells: alternative subcellular enzyme compartmentation may contribute to carcinogenesis by Leung, Yuet-Kin et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Open Access Articles Open Access Publications by UMMS Authors 
2005-05-04 
Overexpression of cytochrome P450 1A1 and its novel spliced 
variant in ovarian cancer cells: alternative subcellular enzyme 
compartmentation may contribute to carcinogenesis 
Yuet-Kin Leung 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs 
 Part of the Cancer Biology Commons, Medical Pathology Commons, and the Surgery Commons 
Repository Citation 
Leung Y, Lau K, Mobley JA, Jiang Z, Ho S. (2005). Overexpression of cytochrome P450 1A1 and its novel 
spliced variant in ovarian cancer cells: alternative subcellular enzyme compartmentation may contribute 
to carcinogenesis. Open Access Articles. https://doi.org/10.1158/0008-5472.CAN-04-3771. Retrieved 
from https://escholarship.umassmed.edu/oapubs/352 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles 
by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
Overexpression of Cytochrome P450 1A1 and Its Novel Spliced
Variant in Ovarian Cancer Cells: Alternative Subcellular Enzyme
Compartmentation May Contribute to Carcinogenesis
Yuet-Kin Leung,
1
Kin-Mang Lau,
1
James Mobley,
1
Zhong Jiang,
2
and Shuk-Mei Ho
1,3,4
Departments of 1Surgery, 2Pathology, 3Cell Biology, and 4Physiology, University of Massachusetts Medical School, Worcester, Massachusetts
Abstract
Epithelial ovarian cancer derived from the human ovarian
surface epithelium (HOSE) is the leading cause of death from
gynecologic malignancies among American women. Metabolic
activation of endogenous and exogenous chemicals by
cytochrome P450 (CYP) class I enzymes has been implicated
in its etiology. In this study, we showed overexpression of
CYP1A1 mRNA, but not CYP1B1 transcripts, in ovarian cancer
cell lines when compared with primary cultures or immor-
talized HOSE cell lines. Importantly, we identified a novel,
enzymatically active, spliced variant of CYP1A1 (CYP1A1v)
formed by excision of an 84-bp cryptic intron in exon 2.
CYP1A1v is overexpressed in ovarian cancer cell lines and
exhibits a unique subcellular distribution restricted to the
nucleus and mitochondria, contrary to the endoplasmic
reticulum localization of the wild-type enzyme. In concor-
dance, total CYP1A1 activity, as measured by the ethoxyre-
sorufin O-deethylase assay, was detected in mitochondrial,
nuclear, and microsomal fractions of ovarian cancer cells but
was notably absent in all subcellular fractions of HOSE cells.
Immunocytochemistry studies in 30 clinical specimens
revealed overexpression of CYP1A1 in various types of ovarian
cancers compared with benign epithelia and frequent locali-
zation of the enzyme to cancer cell nuclei. Forced expression
of CYP1A1wt or CYP1A1v in HOSE cells resulted in nuclear
localization of the enzyme and acquisition of anchorage-
independent growth, which was further exacerbated following
exposure to benzo(a)pyrene or 17B-estradiol. Collectively,
these data provided the first evidence that CYP1A1 over-
expression and alternative splicing could contribute to
ovarian cancer initiation and progression. (Cancer Res 2005;
65(9): 3726-34)
Introduction
In the United States, ovarian cancer is the leading cause of death
from gynecologic neoplasms (1). About 23,000 cases are diagnosed
each year and 14,000 women die from the disease. The majority
(90%) of ovarian cancers are epithelial cancers arising from the
human ovarian surface epithelium (HOSE), which is a simple
squamous-to-cuboidal mesothelium covering the ovary.
Epidemiologic studies suggest dietary/environmental factors,
such as high levels of meat consumption (2), caffeine intake (3),
and cigarette smoking (4), are risk factors for ovarian cancer. In
these instances, cytochrome P450 (CYP) 1A1 may play a major role
in the metabolic activation of procarcinogens to carcinogens. For
example, it is known that polycyclic aromatic hydrocarbons (PAH),
by-products of incomplete combustion and pyrolysis of fossil fuels
and organic matters, such as tobacco leaf, are direct carcinogens
of HOSE cells (5). Other environmental pollutants, such as the
halogenated aryl hydrocarbon 2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCDD), a by-product of some herbicides, are potent inducers of
the enzyme (6) and may therefore exacerbate the metabolic
activation of other procarcinogens to carcinogens. In a rat model,
chronic treatment with TCDD promoted development of ovarian
tumors (7). An industrial accident in Seveso, Italy, in 1976 contami-
nated the area with TCDD and raised ovarian cancer incidence
among female residents (8). Similarly, endogenous factors, parti-
cularly estrogens, such as 17h-estradiol (E2) and estrone (E1), could
be converted into catechol estrogens and other genotoxic
metabolites via the action of CYP1A1 as well as CYP1B1 (9, 10).
These reactive metabolites are known carcinogens of mammary
cells (10) and may also be involved in the neoplastic transformation
of HOSE cells, which are exposed to high levels of follicular
estrogens associated with ovulation (11, 12). In this regard, women
who carry polymorphic variants that confer higher CYP1A1 enzyme
activity, such as the Ile/Val or Val/Val polymorphism in exon 7 (13),
are at higher risk for ovarian cancer (14, 15). Additionally, positive
interactions have been shown between tobacco smoking and
CYP1A1 (MspI) polymorphism (16) as well as between high caffeine
consumption and Ile/Val polymorphism (14) in ovarian cancer
patients. Based on findings from these studies, we hypothesized
that CYP1A1 plays a key role in mediating the carcinogenicity of
specific endogenous and exogenous chemicals on the ovarian
surface epithelium.
Alternative splicing is an important mechanism for generating
proteomic complexity and functional diversity (17). Removal of
intron sequences from pre-mRNA is carried out by a ribonucleo-
protein complex called a spliceosome. Most splicing events occur
where the intron starts with GT and ends with AG, the so-called
GT-AG rule. However, completion of the Human Genome Project
has revealed other noncanonical splice pairs, including AT-AC (18),
along with novel spliceosomes (19). New categories of alternative
splicing events, including insertion of cryptic exons or excision of
cryptic intron, production of exon/intron isoforms, and intron
retention, have also been characterized (20, 21). However, few of
these new splicing mechanisms have been directly implicated in
the pathogenesis of cancers.
In this study, we identified a novel CYP1A1 variant (CYP1A1v)
that is formed via excision of an 84-bp cryptic intron within exon 2
of the gene. Thus, the goals of this study were (a) to compare
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the expression levels of CYP1A1wt and CYP1A1v in normal HOSE
cell lines to those in ovarian cancer cell lines, (b) to investigate
the expression pattern of CYP1A1 in 30 cases of clinical specimens,
(c) to determine whether CYP1A1v is enzymatically active and
compare its subcellular distribution with that of CYP1A1wt, and
(d) to assess whether these isoforms possess transforming poten-
tials when expressed stably in HOSE cell lines in the absence or
presence of procarcinogens, such as benzo(a)pyrene (BaP, a proto-
type PAH) and estrogen (E2, an endogenous estrogen). Our findings
showed that both CYP1A1 isoforms are overexpressed in ovarian
cancer cell lines and clinical specimens. Importantly, CYP1A1v
was found to be enzymatically active and exclusively localized
to the mitochondria and nucleus. Forced expression of either
isoforms induced anchorage-independent growth in HOSE cells,
especially in the presence of BaP and E2. Collectively, these data
provided the first evidence that CYP1A1 overexpression and
alternative splicing could contribute to ovarian cancer initiation
and progression.
Materials and Methods
Cell cultures and cell lines. Four normal primary HOSE cell cultures
(HOSE 27, 20, 17, and 13), four immortalized normal HOSE cell lines (HOSE
301, 306, 636, and 646; ref. 22), and four ovarian cancer cell lines (OVCA 420,
429, 432, and 433; ref. 23) were used in this study. These cells were cultured
and maintained as reported previously (22–24).
Clinical specimens. Human surgical ovarian tissues were collected by
Z.J. at the Department of Pathology, University of Massachusetts Medical
School (Worcester, MA) through routine procedures for histologic diagnosis.
A total of 28 clinical specimens, including 24 ovarian neoplasms (18 serous
adenocarcinomas, 3 mucinous adenocarcinomas, 2 borderline malignant
mucinous tumors, and 1 benign serous cystadenoma), 3 normal ovaries, and
1 pancreatic metastasis to ovary, were included in this study. Paraffin-
embedded tissue sections were cut at 5 Am and mounted on SuperFrost
Plus slides (Erie Scientific, Portsmouth, NH).
Immunohistochemistry. Epitope retrieval of 5 Am paraffin-embedded
tissue sections was achieved through the use of antigen unmasking solution
(Vector Laboratories, Burlingame, CA). A polyclonal rabbit anti-human
CYP1A1 antibody (Human Biologics International, Scottsdale, AZ) with
1:100 dilution was applied. To show specificity of the antibody, pre-
absorption experiment was done using recombinant antigen purchased by
Clontech (Palo Alto, CA). Routine and standard immunohistochemical
procedures were carried out as reported previously (25).
RNA isolation and reverse transcription-PCR analysis. Total RNA was
isolated using TRI-reagent (Sigma, St. Louis, MO) according to protocols
provided by the manufacturer. The forward primer of CYP1A1v recognized
the boundary flanking the deletion of the novel variant of CYP1A1 . Hot-start
PCR using AmpliTaq Gold DNA polymerase (Perkin-Elmer, Norwalk, CT)
was used in all amplification reactions. The PCR program for CYP1A1wt and
CYP1A1v (CYP1A1-F 5V-AAGCACGTTGCAGGAGCTGATG-3V and CYP1A1-R
5V-ACATTGGCGTTCTCATCCAGCTGCT-3V), CYP1A1v (CYP1A1v-F 5V-
GCCTAGTCAACCTGAATGCC-3V and CYP1A1v-R 5V-CGAAGGAA-
GAGTGTCGGAAG-3V), and CYP1B1 (CYP1B1-F 5V-GGCTGGATTTGGA-
GAACGTA-3V and CYP1B1-R: 5V-TCATCACTCTGCTGGTCAGG-3V) was 30
cycles of 1 minute at 94jC, 1 minute at 65jC, and 1 minute at 72jC, except
that glyceraldehyde-3-phosphate dehydrogenase (GAPDH ; GAPDH-F: 5V-
CCACCCATGGCAAATTCCATGGCA-3VGAPDH-R: 5V-TCTAGACGGCAGGT-
CAGGTCCACC-3V) cDNA was amplified at 26 cycles. Signal intensities of
CYP1A1 , CYP1A1v, and CYP1B1 amplimers were normalized to those of
GAPDH to produce arbitrary units of relative abundance.
Direct DNA sequencing analysis. Reverse transcription-PCR (RT-PCR)
products corresponding to CYP1A1 transcripts (wild-type and variant) were
amplified using CYP1A1 primer sets listed above. The DNA bands of interest
were excised and purified and subjected to radiolabeled primer cycle
sequencing using the ThermoSequenase cycle sequencing kit (Amersham
Biosciences Corp., Piscataway, NJ). Two separate rounds of sequencing were
done to ensure reproducibility.
Western blot analysis. Nuclear, mitochondrial, microsomal, and
cytosolic fractions were isolated according to the method of Le Ferrec
et al. (26). Protein concentrations of each fraction were measured by
Bradford assay kit (Bio-Rad, Hercules, CA). Protein (50 Ag) was separated on
10% SDS-polyacrylamide gels and electroblotted onto polyvinylidene
difluoride membranes. Methods and reagents used in Western blot analyses
were described previously (27).
Immunofluorescence staining. All four OVCA cell lines were grown
on coverslips to 80% confluence and then stained with 2 Amol/L
MitoTracker Red CM-H2XROS (Molecular Probes, Eugene, OR) in culture
medium for 30 minutes. Methods of fixation, permeabilization, and
antibody staining were followed as reported previously (28) with following
modifications. Goat polyclonal human CYP1A1 antibody (Gentest,
Woburn, MA) and chick anti-goat antibody tagged with Alexa Fluor 488
(Molecular Probes) were diluted to 1:100 and 1:1,000, respectively. The
control experiment used human CYP1A1 supersomes (Gentest) preab-
sorbed primary antibody.
Ethoxyresorufin O-deethylase activity assay. Ethoxyresorufin O -
deethylase (EROD) activity in different subcellular fractions from various
OVCA cell lines was assessed according to the method of Burke et al. (29).
Reaction mixtures composed of 25 Ag protein and the NADPH regenerating
system were employed. To determine maximal CYP1A1 activity, each
sample was assayed concurrently with and without the addition of 1 unit
CYP reductase (Sigma).
Generation of stable transfected human ovarian surface epithelium
cell lines. Full-length CYP1A1wt and CYP1A1v cDNAs were amplified
using Platinum Taq High Fidelity System (Invitrogen, Carlsbad, CA) and a
specific pair of primers ( forward primer tgctagcATGCTTTTCCCAATCTC-
CAT and reverse primer atttgcggccgcCTAAGAGCGCAGCTGCAT). To
facilitate directional cloning of the PCR products, two restriction sites,
NheI and NotI, were engineered to the 5V end of forward and reverse
primers, respectively (as shown in small letters). PCR reactions were
initiated at 94jC for 3 minutes and followed by 40 cycles of 1 minute at
94jC, 1 minute at 60jC, and 2 minutes at 68jC and continued to
incubate at 68jC for 10 minutes at the end of cycle. PCR products were
gel purified, digested, and cloned into pcDNA3.1 vector (Invitrogen) to
generate pcDNA-1A1wt and pcDNA-1A1v vectors that express full-length
transcripts of CYP1A1wt and CYP1A1v, respectively. Identity and reading
frame of pcDNA-1A1wt and pcDNA-1A1v were confirmed by DNA
sequencing (Macrogen, Inc., Seoul, Korea). Each of the immortalized
HOSE cell lines (HOSE 301, 306, 636, and 642) was stably transfected
with pcDNA-1A1wt and pcDNA-1A1v, separately, using LipofectAMINE
Plus reagent (Invitrogen). Empty vector was also stably transfected into
HOSE cell lines to serve as a control. Stable transfectants of HOSE cell
lines carrying the empty vector, pcDNA-1A1wt , and pcDNA-1A1v were
named as CTL, WT, and V, respectively. For each of the four HOSE lines,
we generated their respective CTL, WT, and V derivatives.
Soft agar assay. Stable transfected HOSE cells were trypsinized,
counted, and mixed with 0.4% Noble agar in complete medium with 5%
charcoal-stripped serum (labeled as UT), charcoal-stripped medium with
1 Amol/L estrogen (labeled as E2), or charcoal-stripped medium with
1 Amol/L BaP at a concentration of 1,250 cells/250 AL and then transferred
into a 0.8% Noble agar precoated 24-well plates. Plates were incubated in
2 medium for up to 4 weeks. The number of colonies formed in soft agar
for each of the four HOSE cell lines transfected with the same vector was
averaged and SDs were calculated.
In silico analyses. Extensive sequence analyses were carried out using
nucleotide and protein BLAST programs provided by National Center
for Biotechnology Information (http://www.ncbi.nlm.nih.gov). DNA
sequences comparison was done using Clustalw from European
Bioinformatics Institute (http://www.ebi.ac.uk/clustalw). Possible signal
sequences and the hydrophilicity/hydrophobicity of CYP1A1 protein were
analyzed using PSORTII (http://psort.ims.u-tokyo.ac.jp/form2.html) and
SwissProt from Swiss Institute of Bioinformatics (http://us.expasy.org/),
respectively.
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Statistical analyses. One-way ANOVA was used to detect significant
differences among the various group means. A multiple range test using the
Tukey-B procedure was employed to compare the individual group means.
Significance was set at P < 0.05 or 0.01.
Results
Identification of a novel CYP1A1v in OVCA cells. In our initial
experiments, when RT-PCR analyses were conducted using a
primer set designed for CYP1A1 , two PCR products of different
sizes were detected in cDNA samples prepared from OVCA cells
(Fig. 1A): a 387-bp product expected to be amplified from wild-type
CYP1A1 transcripts and a smaller (303 bp) product. To minimize
the chances of PCR artifacts, a more stringent annealing
temperature (65jC) was used for all subsequent PCRs. The
smaller-sized fragment was consistently amplified from all
reactions under these conditions. DNA from the smaller band
was isolated and sequenced, revealing that it could be derived from
transcripts of a splicing variant. When compared with the wild-type
transcript, the splicing variant has an 84-bp deletion in exon 2
(Fig. 2A). To our knowledge, its sequence had never been reported.
We therefore concluded that it is a novel splicing variant, which we
here called CYP1A1v. This sequence has since been deposited in
Genbank with the assigned accession no. AY310359. A new set of
specific primers designed to amplify CYP1A1v covering the variant-
specific exon junction was used for subsequent semiquantification
of the variant transcripts.
Overexpression of CYP1A1wt and the novel CYP1A1v in
OVCA cells compared with human ovarian surface epithelium
cells. Semiquantitative RT-PCR analyses showed that primary
cultures of normal HOSE cells and immortalized HOSE cell lines
expressed minimal levels of CYP1A1wt mRNA and CYP1A1v
mRNA (Fig. 1A and B). In contrast, the four OVCA cell lines
consistently showed overexpression of the two CYP1A1 transcripts
compared with levels found in HOSE cell cultures. About a 5-fold
increase in the CYP1A1wt mRNA and a 10-fold increase in
CYP1A1v mRNA were observed in the OVCA cell lines on average
(Fig. 1B). In contrast, there was no observable difference in
CYP1B1 mRNA expression levels among the various HOSE and
OVCA cell lines.
Overexpression of CYP1A1 protein and atypical nuclear
staining in human ovarian cancer specimens. A total of 27
clinical specimens, including 24 ovarian neoplasms (18 serous
adenocarcinomas, 3 mucinous adenocarcinomas, 2 borderline
malignant mucinous tumors, and 1 benign serous cystadenoma)
and 3 normal ovaries were immunostained with a polyclonal
rabbit anti-human CYP1A1 antibody to assess their expression of
CYP1A1 proteins (Fig. 3). Strong cytoplasmic (nonnuclear) staining
was restricted to the cancer cells of serous and mucinous
adenocarcinomas but was more widespread in stromal cells (Fig.
3A-C). Some cancer cells in these specimens showed both
cytoplasmic and nuclear staining (Fig. 3B). CYP1A1 protein was
also immunolocalized in the epithelial cells of borderline
mucinous lesions (Fig. 3A). The majority of serous and mucinous
carcinoma cells showed immunopositivity in both nuclei and
cytoplasmic staining (Table 1). Expression of cytoplasmic and
nuclear CYP1A1 seems to decline concomitantly in types of
carcinoma with lower malignancy. CYP1A1 immunonegativity was
detected in benign serous cystadenoma (Fig. 3D) and normal
human ovary. The one human tissue specimen of pancreatic
metastasis to ovary in this study showed no detectable CYP1A1
protein expression (data not shown).
Overexpression of CYP1A1wt protein and CYP1A1v protein
in ovarian cancer cell lines and exclusive localization of
CYP1A1v in cell nucleus and mitochondria. Western blot
analyses revealed that wild-type and variant CYP1A1 protein were
expressed at very low levels in HOSE cells but were abundant in
OVCA cell lines (Fig. 4A). Subcellular fractionation of OVCA cells
revealed that the wild-type and variant proteins are localized in
different cellular compartments. CYP1A1wt was principally associ-
ated with the microsomal fraction, whereas CYP1A1v resided
predominantly in the nuclear and mitochondrial compartments of
OVCA cells (Fig. 4A). The unique subcellular distribution of
CYP1A1v is specific, because no wild-type enzyme was colocalized
to these fractions. Interestingly, neither protein was detected at any
significant level in the cytosolic fraction. The unusual localization of
CYP1A1v in the nucleus and mitochondria was also confirmed by
immunofluorescence microscopy (Fig. 4B). The fluorescence signals
of CYP1A1 immunoreactivity (Fig. 4B , 2) completely coincided with
signals from nuclear (blue ; Fig. 4B , 1) and mitochondrial (red ;
Fig. 4B , 3) trackers in contrast to the results obtained with an
Figure 1. A, relative abundance of CYP1A1wt , CYP1A1v , CYP1B1 , and
GAPDH transcripts in different normal, immortalized normal, and ovarian
cancer cells. RT-PCRs were done on 1 Ag RNA using primer sets for
corresponding genes. Representative fluorographs of the RT-PCR products.
Bottom bands appearing exclusively in cancer cells were purified and
sequenced. B, relative abundance of CYP1A1wt (white ), CYP1A1v (gray ), and
CYP1B1 (black ) transcripts in HOSE and OVCA cells. Columns, mean relative
abundance of gene transcripts from all primary cultures of normal and
immortalized HOSE cells and those from the four OVCA cell lines [n = 12
(HOSE); n = 12 (immortalized HOSE); and n = 12 (OVCA)]; bars, SD. One-way
ANOVA was applied to calculate the statistical significance of CYP1A1wt and
CYP1A1v mRNA expression among HOSE, immortalized HOSE, and OVCA
samples (P < 0.01).
Cancer Research
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antibody preparation preabsorbed with the antigen (Fig. 4B , 6).
The low levels of CYP1A1 signal observed in the nonmitochon-
drial compartment of the cytoplasm (Fig. 4B , 4 and 8-10) could
be due to association of CYP1A1wt with the microsomes.
Computer-aided analysis of the CYP1A1v sequence. Analysis
of the full-length sequence revealed that the 84-bp deletion is in-
frame and would not cause premature termination (Fig. 2B),
implying that the variant protein will have 28 fewer amino acid
residues (amino acids 223-249; Fig. 2A) in its NH2-terminal region
than the wild-type protein. An extensive Genbank search found no
previous report of the variant. However, a human EST clone
(CB267342) in an adipocyte cDNA library was found to correspond
to our reported sequence of the variant. This evidence strongly
supports our belief that CYP1A1v exists in some other tissues and
is not an artificial PCR product.
By comparing the sequence of CYP1A1v mRNA to that of
the wild-type transcript, eight possible splice junction pairs
were recognized (i.e., the dinucleotides upstream and down-
stream of the splice site could be CC-TC, CT-CC, TG-CC, GA-CT,
AA-TG, AT-GA, TA-AA, or AA-AT; Fig. 2C). However, none of
these obeyed the GT-AG rule (30), suggesting that a non-
canonical splice site is responsible for alternative splicing of the
CYP1A1 pre-mRNA. Moreover, among the eight possible sites,
because only one splice junction pair, AA-AT, has been suggested
to exist by statistical analysis of all annotated genes in the
mammalian genome (18), it may be the pair involved in splicing
of this variant.
To investigate why only the CYP1A1v (not the wild-type protein) is
targeted to the nucleus and mitochondria, an extensive in silico
search of possible signaling peptides was done. A putative bipartite
basic nuclear localization signal (NLS) was identified in the CYP1A1
amino acid sequence from residues 341 to 357 (RKIQEELDT-
VIGRSRRP; Fig. 2A), which matches the consensus motif
(K/R)2X10-12(K/R)3 of nucleoplasmin (31). However, these searches
failed to identify a mitochondrial matrix-targeting signal, most
commonly composed of positive charge and hydroxylated residues
(32), in the CYP1A1v. Of interest, hydrophobicity analysis revealed a
decrease in the overall hydrophobicity in the NH2-terminal region of
CYP1A1, most markedly around amino acids 230 to 260, which
encompasses the deleted region (33). Thus, perturbation in this
general area may result in the formation of a functional
mitochondrial targeting signal.
According to a recent molecular modeling study of human
CYP1A1 (34), both resorufins and BaP are primarily stabilized by
hydrophobic interactions in the substrate binding pocket. Within
this substrate binding pocket, two key amino acid residues in
helix F responsible for substrate stabilization (amino acids 224
and 228; Fig. 2A) were found to be deleted from the CYP1A1v.
Loss of these amino acids may result in alterations in substrate
specificity and/or binding affinity in the variant protein.
CYP1A1v in both nucleus and mitochondria is active in
ethoxyresorufin O-deethylase assay. To determine whether the
mitochondria- and nucleus-localized CYP1A1 protein, presumably
derived from the CYP1A1v, is catalytically active, the EROD assay
was done after subcellular fraction of ovarian cancer cell lines
(OVCA 429, 432, and 433) in the presence and absence of
exogenous CYP oxidoreductase. The enzyme activity found in
subcellular fractions of each cell lines were determined and
averaged (Fig. 5). In the absence of exogenous CYP oxidoreduc-
tase, the highest EROD activity was detected in the nuclear
fraction followed by the mitochondrial and microsomal fractions,
whereas the cytosolic fraction was devoid of EROD activity. In the
presence of extra CYP oxidoreductase, significantly higher levels
(3- to 4-fold increases) of EROD activities were found in all
fractions. The greatest increase was observed in the microsomal
fraction followed by the mitochondrial and nuclear fractions.
Under this condition, a low level of cytosolic EROD activity was
also detected. We noticed that NAPDH oxidoreductase plays a
greater role in enhancing the enzyme activity of CYP1A1wt and
CYP1A1v in ovarian cancer cell lines. It seems that the activities
of both CYP1A1wt and CYP1A1v are limited by low levels of
oxidoreductase activity in ovarian cancer cells when compared
with TCDD-stimulated MCF-7 cells (data not shown). Because we
have shown exclusive localization of the CYP1A1v in the
mitochondria and nucleus by Western blotting, together with
previously reported association of CYP1A1wt with the micro-
somes (35), the EROD data now strongly support the notion that
the CYP1A1v is catalytically as active as CYP1A1wt.
CYP1A1wt and CYP1A1v are both involved in benzo(a)py-
yrene- or 17B-estradiol-induced cellular transformation. This
experiment sought to determine (a) whether overexpression of
CYP1A1wt and CYP1A1v in HOSE cells also results in their
protein products localized to different cellular compartment, (b)
Figure 2. Schematic diagram showing CYP1A1v protein and mRNA. A,
location of 28–amino acid residues (deletion ) and NLS.!, amino acids 224 and
228 in helix F were deleted from the variant;5, hotspot (amino acid residue 462)
of CYP1A1 polymorphism. B, Clustalw alignment of CYP1A1v against
CYP1A1wt. The deleted cDNA region (84 bp) is highlighted (bold ) in the
CYP1A1wt sequence. Right, cDNA positions of both wild-type and variant
transcripts. C, eight possible modes of processing CYP1A1 pre-mRNA. Various
donor and acceptor splice sites are highlighted.
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whether overexpression of CYP1A1wt or CYP1A1v induces
neoplastic transformation per se in HOSE cells, and (c) whether
overexpression of the enzyme mediates cellular transformation
caused by an endogenous/exogenous procarcinogen. The soft
agar colony formation assay was used to measure acquisition of
anchorage-independent growth potential in the four HOSE cell
lines (HOSE 301, 306, 636, and 646), each stably transfected with
empty pcDNA3.1 (HOSE-CTL), pcDNA-1A1wt (HOSE-WT), or
pcDNA-1A1v (HOSE-V). BaP, a major PAH produced during
cigarette smoking (36), was used as a prototype exogenous
environmental procarcinogen. E2, the major circulating and
follicular estrogen, was chosen for our study because ovarian
surface epithelial (OSE) cells are often exposed to high levels of
this steroid around ovulation or when trapped in the stroma as
inclusion cysts (11). Both BaP and E2 are the known substrates
for CYP1A1, and their metabolites are carcinogenic (9, 10, 37).
All four HOSE-CTL cell lines expressed no detectable CYP1A1wt
or CYP1A1v mRNA as shown by semiquantification of the
transcripts by RT-PCR (Fig. 6A). As expected, HOSE-V cell lines
expressed high levels of CYP1A1v transcript and no detectable
CYP1A1wt mRNA (Fig. 6A , top). Surprisingly, HOSE-WT cell lines, in
addition to high levels of CYP1A1wt mRNA, also expressed
detectable levels of CYP1A1v transcripts, likely products of
alternative splicing of the wild-type transcript (Fig. 6A , middle).
Exposure of HOSE cell lines (CTL, WT, or V) to BaP and E2 did not
alter expression levels of CYP1A1wt , CYP1A1v, or CYP1B1 .
Two approaches were used to determine whether HOSE-WT and
HOSE-V cell lines overexpressed the CYP1A1s that exhibited extra–
endoplasmic reticulum (ER) localization. EROD assays were done
on subcellular fractions of three types of stable transfected HOSE
cell lines (HOSE-CTL, HOSE-WT and HOSE-V) and revealed the
following: (a) the enzyme activities of CYP1A1 were elevated in
Table 1. Expression of CYP1A1 in ovarian carcinoma
Type of tumors No. cases Cytoplasmic staining* Nuclear staining
<75% 30-75% >30% <75% 30-75% >30%
Serous cancer 20 11 9 0 4 10 6
Mucinous cancer 5 4 1 0 1 4 0
Serous, low malignant potential
(of borderline malignancy)
3 2 1 0 1 2 0
Mucinous, low malignant potential
(of borderline malignancy)
2 0 2 0 0 1 1
Total 30 17 (57%) 13 (43%) 0 (0%) 6 (20%) 17 (57%) 7 (23%)
100% 100%
*Nonnuclear region includes mitochondria, microsomes, and cytosol.
Figure 3. Immunohistochemical stains for CYP1A1 on human
ovarian tumors. A, serous tumors of borderline malignancy (of low
malignant potential) showing positive (brown ) staining for CYP1A1
in tumor epithelial cells and negative staining in adjacent stroma
(boxed area). B, poorly differentiated serous adenocarcinoma
showing cytoplasmic staining and nuclear staining for CYP1A1 in
cancer cells (arrows and inset ). C, mucinous adenocarcinoma
also showing expression of CYP1A1. D, benign ovarian
cystadenoma was CYP1A1 immunonegative. All sections were
counterstained with hematoxylin.
Cancer Research
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both HOSE-WT and HOSE-V cell lines when compared with HOSE-
CTL cells, (b) the enzyme activities were predominantly detected in
the nuclear fractions (Fig. 6B), and (c) little to no enzymatic
activities were present in the mitochondrial fraction. Results from
immunofluorescence assays (data not shown) confirmed this
observation. Of interest to note, the quantity of mitochondria in
those HOSE cell lines was extremely low when compared with
OVCA cells (data not shown).
As shown in Fig. 6C , the soft agar assay revealed that (a)
exposure of HOSE cell lines transfected with the empty vector
(HOSE-CTL) to the procarcinogens BaP and E2 did not cause
significant increases in soft agar colony formation potentials in
these cell lines, (b) stable transfection of HOSE cell lines with
pcDNA-1A1wt or pcDNA-1A1v vector significantly increased their
soft agar colony formation potentials by 100% to 200% (P < 0.01) in
the absence of BaP or E2 exposure, and (c) after exposure to BaP or
E2 HOSE-WT and HOSE-V cell lines exhibited additional increases
in soft agar colony formation potentials; the effect of E2 was greater
than that of BaP in both kinds of stable transfectants and greatest
in HOSE-WT cell lines.
Discussion
In this study, we identified a novel CYP1A1v produced by a
splicing event that involves an excision of an 84-bp cryptic intron.
CYP1A1v, which is enzymatically active and is uniquely and
exclusively located in the nucleus and the mitochondria instead
of in the ER, where the wild-type enzyme resides. Importantly,
when HOSE cells were engineered to overexpress CYP1A1wt , this
alternative splicing mechanism generated CYP1A1v from the
mature wild-type transcript. Hence, an overall increase in CYP1A1
gene expression would give rise to both transcripts and proteins
and extend cellular localization of the enzyme to new cellular
compartments. Of significance, we detected higher levels of
CYP1A1wt and CYP1A1v mRNA in four ovarian cancer cell lines
when compared with primary cultures of normal HOSE cells and
four immortalized HOSE cell lines, which express little or no
CYP1A1 transcripts. Immunocytochemistry revealed overexpres-
sion of the enzyme in various types of ovarian cancers with both
cytosolic and nuclear localization. Comparable levels of CYP1A1
activity, as measured by the EROD assay, were found in nuclear,
mitochondrial, and microsomal fractions of OVCA cells but not in
HOSE cells. Enzyme activity in all three compartments depended
on NADPH regeneration. Further investigation showed acquisition
of anchorage-independent growth in HOSE cells engineered to
stably overexpress exogenous CYP1A1wt or CYP1A1v . On exposure
of these cells to BaP or E2 (especially to the steroid, E2), further
enhancement of anchorage-independent growth was observed.
Taken together, these findings provide strong support for an
essential role of CYP1A1 in neoplastic transformation of HOSE cells
likely via metabolic activation of exogenous/endogenous procarci-
nogens and utilization of a unique alternative splicing mechanism
to broaden the distribution of the enzyme to critical organelles.
The overall hypothesis of this study has been summarized in Fig. 7.
Figure 4. A, Western blot analysis of CYP1A1 in various subcellular fractions of
HOSE and OVCA cells. Representative experiment. nucl , mito , mic , and cyto,
fractions isolated from nucleus, mitochondria, microsomes, and cytosol,
respectively. CYP1A1v is uniquely found in nucleus and mitochondria, whereas
CYP1A1wt resides in microsomes. B, immunofluorescence staining. 1 and 5
(blue ), 4V,6-diamidino-2-phenylindole (DAPI ) staining; 2 (green ),
anti-CYP1A1 antibody staining; 6, antigen preabsorbed anti-CYP1A1 antibody
staining; 3 and 7 (red), MitoTracker Red staining; 4 and 8, composite images of
1 to 4 and 5 to 8 , respectively; 9, magnified version of 4 showing the differential
staining of CYP1A1 in mitochondria (orange ) in white arrowheads and
microsomes (green ) in yellow arrowheads; 10, magnified version of negative
control (8 ) using preabsorbed antibody.
Figure 5. EROD activity in different subcellular fractions of OVCA cells. Gray
and black columns, reaction in the absence or presence, respectively, of
exogenous CYP oxidoreductase. Columns, average of measurements from four
OVCA cell lines; bars, SD.
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Splicing events have been characterized and divided into four
different categories (20, 21): insertion of cryptic exons or excision of
crytic introns, production of exon/intron isoforms, and intron
retention. In our study, an 84-bp cryptic intron is spliced from exon
2 of CYP1A1wt , possibly via an AA-AT splice junction pair, as
suggested by our in silico analysis. This is a noncanonical splice pair,
because >96% of pre-mRNA splicing use the conservative GT-AG
pair (18). The involvement of noncanonical splice junction pairs
may be due to poorly conserved 5V and 3V splice sites and/or many
cryptic splice sites (38). Recent findings suggest that introns flanked
by another noncanonical AT-AC pair are excised by a spliceosome
composed of nonclassic types of small nuclear ribonucleoproteins
(19). Interestingly, when HOSE cells are stably transfected with a
CYP1A1wt expression vector, we found that CYP1A1v coexisted with
the wild-type transcript. This finding indicates that the mature
transcripts of CYP1A1wt are susceptible to this splicing event. Thus,
induction of CYP1A1wt overexpression in normal OSE cells by
xenobiotic/endobiotics or physiologic stresses could yield both
transcripts along with their protein products and might extend the
coverage of enzyme to new cellular organelles, where they may
contribute to an imbalance in activation/detoxification of procarci-
nogens. This splicing event may exist in tissues other than the OSE
because we also observed expression of CYP1A1v mRNA in breast
and prostate cancer cells.5
Although a few early reports detected CYP1A1-like enzyme
activity in cell nucleus (39) and mitochondria (40) in rodent
models, the enzyme identities remain unclear. CYP1A1v is the
first human CYP1A1v to be identified and characterized at both
molecular and biological levels. Thus, alternative splicing of
CYP1A1 could be considered a mechanism for targeting the
enzyme to extra-ER locales. Computational analyses identified a
putative bipartite basic NLS, which is masked in the CYP1A1wt.
One can speculate that removal of the cryptic intron results in
the activation of this NLS and nuclear targeting of CYP1A1v.
However, we cannot yet explain the acquisition of the mitochon-
drial matrix targeting signal via deletion of the 84-bp region,
except to hypothesize that the deletion induces an increase in
hydrophobicity in the NH2 terminus of the molecule and creates a
mitochondrial targeting signal (32) for the variant enzyme. Most
of the CYP enzymes residing in the ER have been shown to
depend on NADPH-oxidoreductase for electron transfer (41), and
their activities are enhanced in the presence of an NADPH
regenerating system. Here, we found that the EROD activity in the
mitochondrial, nuclear, and microsomal fractions of ovarian
cancer cells were all elevated in the presence of exogenous
NADPH-oxidoreductase, suggesting that comparable cofactor
requirements exist between the wild-type and the variant enzyme.
Our results strongly support a role for aberrant expression of
CYP1A1 in ovarian carcinogenesis. Exposure of HOSE cells to BaP or
E2 per se did not induce increased expression of the enzyme. In the
absence of CYP1A1 expression, these two procarcinogens were
ineffective in inducing an anchorage-independent growth pheno-
type in these cells. In marked contrast, overexpression of CYP1A1wt
or CYP1A1v in HOSE cell lines significantly increased anchorage-
independent growth potentials of HOSE cells even in the absence of
BaP or E2. Elevated levels of CYP1A1wt and/or CYP1A1v expression
probably had caused neoplastic transformation via activation of
procarcinogens existing in the culture medium per se. Exposing the
5 Unpublished data.
Figure 6. A, expression of CYP1A1wt , CYP1A1v , and CYP1B1 in a
representative HOSE cell line stably transfected with the empty vector (CTL), the
expression vector for CYP1A1wt (WT ), or one for CYP1A1v (V) after a
24-hour treatment with 1 Amol/L estrogen (E2 ), 1 Amol/L BaP, or vehicle
(Untreated ), respectively. RT-PCR was done using the CYP1A1 primer pair
that amplifies both wild-type (solid arrowhead) and variant (close arrowhead)
CYP1A1 transcript (CYP1A1, top ). The CYP1A1v -specific primer pair was
used to amplify the variant only (CYP1A1v, middle ) and the CYP1B1 -specific
primer set for the CYP1B1 mRNA (CYP1B1, bottom ). B, HOSE cell lines stably
transfected with empty vector (HOSE-CTL, white columns ), the CYP1A1wt
expression vector (HOSE-WT, gray columns ), or the CYP1A1v expression
vector (HOSE-V, black columns) were subfractionated by differential
centrifugation. Different fractions of HOSE-CTL, HOSE-WT, and HOSE-V cell
extracts were obtained and EROD assay was done. Experiments were done
as suggested in Materials and Methods. Average fold of change and
experiment was done in triplicate. C, anchorage-independent growth potentials
were measured as number of colonies formed in soft agar for HOSE cell
lines stably transfected with empty vector, the CYP1A1wt expression vector, or
the CYP1A1v expression vector. White , gray , and black columns, results
for HOSE cell lines stably transfected with the empty pcDNA3.1, pcDNA-1A1wt,
or pcDNA-1A1v vector, respectively. Untreated , E2 , and BaP, three types of
stable transformed HOSE cell lines in soft agar exposed to medium
alone, medium with 1 Amol/L E2, or medium with 1 Amol/L BaP, respectively.
Columns, mean number of colonies formed in soft agar from all stable
transfectants from all four HOSE cell lines; bars, SD. One-way ANOVA
was applied to calculate the statistical significance among different groups.
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stable transfectants to BaP or E2 increased soft agar colony
formation in both HOSE-WT and HOSE-V cell lines. Of interest is
the marked elevation of soft agar colony formation in HOSE-WTcell
cultures exposed to E2 when compared with HOSE-V cell lines. In
contrast, BaP elicited roughly the same response in both types of
stable transfectants. Because the overexpression of CYP1A1 in
HOSE-WTand HOSE-V cell lines were localized primarily in nuclear
compartment possibly due to low abundance of mitochondria in
these cell lines, we suggest that nuclear localization of CYP1A1 is
sufficient to mediate BaP-induced neoplastic transformation,
whereas the E2-induced transformation may involve the presence
of the enzyme in multiple subcellular organelles. Indeed, BaP
carcinogenicity is believed to bemediated by the translocation of the
procarcinogen to the cell nucleus followed by formation of the
mutagenic metabolite BaP-7,8-diol 9,10-epoxide and DNA adducts,
which in turn initiate mutagenesis (42, 43).
On the contrary to BaP, estrogen carcinogenicity is much more
complex and involves multiple phase I and II enzymes with
different subcellular locales. Estrogens are converted to catecho-
lestrogens (2-OH and 4-OH estrogens) and estrogen quinones,
which are genotoxic, via CYP1A1 and CYP1B1 metabolic
activation (9, 10). Catechol-O-methyltransferase catalyzes the
methylation of catechol estrogens to methoxyestrogens, which
may reduce the potential for genomic damage and suppress cell
proliferation via enhancement of 2-MeOE2 formation (44, 45).
Aberrant or altered expression of these estrogen metabolic
enzymes is implicated in the initiation of human breast and
endometrial tumors (9, 10, 46, 47). Analogous information has
been scarce for ovarian carcinogenesis. The human ovarian
epithelium is routinely exposed to high levels of estrogens such as
those produced during the follicular phase of each female cycle.
Alternatively, the ovarian epithelium is exposed to abnormal
levels of stromal estrogens with the formation of inclusion cysts,
which in fact have been proposed as the origin of epithelial
ovarian cancer (48). In general, CYP1A1 produces mostly 2-OH
estrogens, but a significant amount of 4-OH estrogens is
generated simultaneously (49). It has been shown that 4-OH
estrogens are more carcinogenic than 2-OH estrogens in a
mammary epithelial cell model (10). Whether a similar scenario
exists for OSE remains to be investigated in future experiment.
In summary, we here provide the first evidence that CYP1A1 is
overexpressed in ovarian cancer cell lines and ovarian cancers. We
also report the identification of a novel variant of CYP1A1 that is
enzymatically active and resides exclusively in cell nucleus and
mitochondria. Our data suggest that a noncanonical splice group is
responsible for the removal of a cryptic intron from the CYP1A1
transcript. These findings raise the possibility that alternative
splicing underlies increased functional diversity of CYP1A1 by
increasing its subcellular coverage. They also suggest that chronic
or repeated induction of CYP1A1 expression in HOSE cells would
result in expression of the enzyme in multiple cellular organelles,
leading to an imbalanced detoxification-activation homeostasis of
xenobiotics/endobiotics, a mechanism long suspected to induce
neoplastic transformation.
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Figure 7. Schematic diagram summarizing the
hypothesis of this study. In normal HOSE cells, the
expression level of CYP1A1wt (diamond ) is low or
undetectable. On exogenous (environmental factors) or
endogenous (hormone factors) stimuli, CYP1A1wt can be
significantly induced in HOSE cells. Some of the
CYP1A1wt transcripts can be partially converted into
CYP1A1v (broken diamond ) by alternative splicing via
cryptic intron excision. The protein products of CYP1A1v
mRNA are targeted to nucleus and mitochondria instead of
microsomes (ER) where CYP1A1wt resides. Both
CYP1A1wt and CYP1A1v can metabolize various kinds of
procarcinogens into highly reactive carcinogens, which
in turn attack protein and DNA within their compartments.
As a result of DNA adduct formation, DNA mutations
accumulate and eventually impair genome stability. HOSE
can be finally transformed with more cancer phenotypes.
With the perpetual stimulation of activated carcinogens,
transformed cells may progress to more advanced stage.
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